Bioprosthetic valve thrombosis after transcatheter aortic valve replacement and pulmonary embolism due to heparin-induced thrombocytopenia: a case report.
Fiche publication
Date publication
août 2023
Journal
Frontiers in cardiovascular medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr OHANA Mickaël
Tous les auteurs :
Faucher L, Marchandot B, Carmona A, Ohana M, Trimaille A, Morel O
Lien Pubmed
Résumé
Bioprosthetic valve thrombosis is a complication of transcatheter aortic valve replacement (TAVR). It is believed to be platelet independent, mainly driven by contact phase activation, and more likely to be targeted by oral anticoagulant (OAC).
Mots clés
TAVR—transcatheter aortic valve replacement, argatroban, bioprosthetic valve dysfunction, heparin-induced thrombocytopenia, intensive unit care, pulmonary embolism, thrombosis—etiology
Référence
Front Cardiovasc Med. 2023 08 8;10:1164432